Lung transplants save lives, but they remain the most challenging of all major organ transplants in terms of long-term survival. The median survival after a lung transplant currently stands at about 5.8 years, which trails well behind the outcomes seen after kidney, liver, or heart transplantation.1PubMed Central. Outcomes after lung transplantation That number has been steadily improving over the decades, though, and individual outcomes vary enormously depending on your underlying disease, the type of procedure, the transplant center, and even how carefully you take your medications afterward.
How Lung Transplant Survival Compares to Other Organs
The lungs are uniquely vulnerable among transplanted organs. They are the only solid organ in direct contact with the outside environment every time you breathe, exposing the graft to bacteria, viruses, fungi, and air pollution around the clock. They also have an intricate blood supply and a massive surface area of delicate tissue that must heal and function immediately after surgery. These features make infection and rejection more persistent threats than they are for, say, a transplanted kidney sitting deep inside the abdomen.
Studies comparing outcomes across organ types consistently place lung recipients at a disadvantage. An analysis of solid organ transplant recipients found that lung transplant patients had the lowest rates of both overall patient survival and complication-free survival when compared with heart, kidney, and liver recipients.2PubMed Central. Perioperative complications and mid-term outcomes in total hip and knee joint arthroplasty among solid organ transplant recipients: lowest reoperation-free survival and patient survivorship in lung transplant recipients This gap is not a sign that the procedure is failing; it reflects the biological difficulty of keeping a transplanted lung functioning in a body that is constantly trying to reject it while the organ is simultaneously fending off airborne threats.
The First Days and Weeks After Surgery
The earliest and most dangerous complication is called primary graft dysfunction, a form of acute lung injury that develops within the first 72 hours. When severe graft dysfunction occurs, outcomes are grim: 30-day mortality runs above 40%, compared with roughly 6% in patients whose new lungs function normally right away.3American Journal of Respiratory and Critical Care Medicine. The Effect of Primary Graft Dysfunction on Survival after Lung Transplantation Among all patients who died within the first month, nearly half had primary graft dysfunction. The condition resembles acute respiratory distress and is thought to stem from injury to the donor lungs during procurement, preservation, and reperfusion. It is one of the main reasons transplant teams invest so heavily in donor lung assessment and preservation techniques.
Fortunately, recent data on 30-day mortality across the broader transplant population are encouraging. Under the newest allocation system in the United States, 30-day mortality sits at about 2.3%, suggesting that most recipients clear the acute surgical window successfully.4PubMed. Early outcomes of lung transplantation under the composite allocation score system The challenge is what comes later.
Chronic Lung Allograft Dysfunction, the Long-Term Threat
If you survive the first year in good shape, the main risk to your transplanted lung shifts to chronic lung allograft dysfunction, or CLAD. This umbrella term describes a progressive, largely irreversible decline in lung function that develops months or years after surgery.5PubMed Central. Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms CLAD is the single biggest barrier to better long-term outcomes, and it comes in two main forms. The more common one, bronchiolitis obliterans syndrome, involves scarring and narrowing of the small airways. The rarer but more aggressive form, restrictive allograft syndrome, stiffens the lung tissue itself. Survival after a diagnosis of bronchiolitis obliterans syndrome ranges from roughly three to five years, while restrictive allograft syndrome is far worse, with median survival of only about six to eighteen months after diagnosis.6PubMed Central. Chronic lung allograft dysfunction phenotypes and treatment
Researchers are actively investigating what triggers CLAD. One important factor is the development of donor-specific antibodies, where your immune system produces antibodies targeting proteins on the donor lung. A study of over 350 recipients found that about 17% developed these antibodies, and those patients had significantly worse outcomes: persistent antibodies roughly tripled the risk of losing the graft.7PubMed. Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation Even transient antibodies that appeared and disappeared raised the risk of CLAD. These findings have spurred interest in monitoring antibody levels closely after transplant and exploring targeted therapies. Interestingly, a separate study found that when donor-specific antibodies were already present before surgery, they did not significantly increase mortality or CLAD rates, though they did raise the odds of prolonged time on a ventilator and early rejection episodes.8Annals of the American Thoracic Society. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies The immune picture, in other words, is complicated and still being worked out.
How the Underlying Disease Shapes Your Odds
Not everyone who needs a lung transplant faces the same prognosis afterward. The disease that destroyed your original lungs continues to influence survival in subtle ways. COPD (chronic obstructive pulmonary disease), idiopathic pulmonary fibrosis, and cystic fibrosis are the three most common reasons people need new lungs, and each carries its own risk profile.
For COPD patients specifically, one study found that those who also had elevated pressure in the blood vessels of the lungs (pulmonary hypertension) had notably worse outcomes: one-year survival of about 77% versus 86% for COPD patients without that complication. In statistical models, the risk of dying within a year was about 74% higher in the pulmonary hypertension group.9PubMed. Pulmonary hypertension is associated with increased post-lung transplant mortality risk in patients with chronic obstructive pulmonary disease The same complication did not significantly affect survival in patients transplanted for pulmonary fibrosis or cystic fibrosis, suggesting something specific about the COPD-plus-pulmonary-hypertension combination worsens outcomes.
Single Lung Versus Double Lung Transplant
Transplant teams must decide whether to replace one lung or both, and the evidence increasingly favors replacing both when the patient can tolerate the bigger operation. A meta-analysis found that single lung transplants had significantly lower three-year and five-year survival rates compared with double lung transplants in COPD patients.10PubMed Central. Double lung transplantation is better than single lung transplantation for end-stage chronic obstructive pulmonary disease: a meta-analysis
Even within single lung transplants, the side matters. An analysis of COPD recipients found that left single lung transplants carried a higher risk of death compared with right single lung transplants, with adjusted five-year survival of about 51% for left versus 57% for right. Double lung recipients fared best at about 58% five-year survival, though the gap between double and right single lung transplants was not statistically significant.11PubMed Central. Right single lung transplantation or double lung transplantation compared with left single lung transplantation in chronic obstructive pulmonary disease The left lung is smaller and anatomically different, which may contribute to the disparity. For most patients today, the trend at high-volume centers has shifted heavily toward bilateral transplants.
Donor Selection and “Extended Criteria” Donors
One of the biggest bottlenecks in lung transplantation is the shortage of suitable donor organs. Only a fraction of deceased donors have lungs healthy enough to transplant, which has led transplant teams to push the boundaries of which donor organs they will accept. So-called extended criteria donors, those who are older, have a smoking history, or have other characteristics traditionally considered less ideal, are increasingly being used.
The question of whether these donors produce worse outcomes does not have a simple answer. One national analysis found no difference in 30-day, 90-day, or one-year survival between recipients of extended criteria and standard donor organs.12PubMed. National Trends in Extended Criteria Donor Utilization and Outcomes for Lung Transplantation However, a separate review of the same national registry painted a more nuanced picture: extended criteria donors were associated with a roughly 40% higher risk of death overall, and the combination of a high-acuity recipient with an extended criteria donor produced the worst outcomes, with about a 1.8-fold increase in the risk of dying compared with a lower-acuity recipient receiving a standard organ.13PubMed. The use of extended criteria donors decreases one-year survival in high-risk lung recipients: A review of the United Network of Organ Sharing Database
One particularly encouraging finding concerns older donors. A propensity-matched study comparing donors aged 70 and older with younger donors found no difference in five-year patient survival (about 74% in both groups) or in rates of chronic graft dysfunction.14PubMed Central. Lung Transplant Outcome From Selected Older Donors (≥70 Years) Equals Younger Donors (<70 Years): A Propensity-matched Analysis The key word is “selected.” When older donor lungs are carefully screened and found to be in good shape, the recipient does just as well. The implication is that donor age alone should not disqualify organs, which could meaningfully expand the donor pool.
Ex Vivo Lung Perfusion Is Expanding the Donor Pool
A technology that has genuinely changed the landscape is ex vivo lung perfusion, or EVLP. Instead of simply cooling a donor lung and rushing it to the recipient, transplant teams can now connect the organ to a machine outside the body that warms it, ventilates it, and pumps a special solution through its blood vessels. This allows the team to assess the organ’s function in real time and even rehabilitate marginal lungs that would previously have been discarded.
In the largest national series of EVLP recipients in the United States, 180-day survival was 92% for both EVLP and standard transplants, with no significant difference in mortality or acute rejection rates after statistical adjustment.15PubMed Central. Lung transplantation after ex vivo lung perfusion: Early outcomes from a US national registry The technology is not making transplants more dangerous; it is making more transplants possible. At one major center, EVLP availability was associated with a significant increase in the rate of transplantation and a dramatic reduction in median wait time, from about 126 days down to 66 days.16PubMed Central. Evaluating the Impact of Ex Vivo Lung Perfusion on Organ Transplantation: A Retrospective Cohort Study For patients deteriorating on the waiting list, that difference can be lifesaving.
How You Get Prioritized on the Waiting List
In the United States, lung allocation was historically based on wait time alone, which meant the sickest patients sometimes died before they reached the top of the list. The Lung Allocation Score system, introduced in 2005, attempted to fix this by assigning a score based on urgency and expected benefit. But higher scores correlated with worse post-transplant outcomes. Patients with scores of 60 or above had a significantly increased risk of death after transplant, and those with scores above 80 faced roughly double the mortality risk compared with lower-scoring recipients.17PubMed Central. Increasing Lung Allocation Scores predict worsened survival among lung transplant recipients
In 2023, the U.S. system transitioned to a new Composite Allocation Score that also incorporates geographic equity and biological compatibility factors. Early data are encouraging: waitlist mortality dropped, transplant rates increased, and short-term post-transplant survival remained similar to the older system, with nine-month survival of about 92%.4PubMed. Early outcomes of lung transplantation under the composite allocation score system Another analysis found improved six-month and one-year survival under the new system and a striking reduction in rejection treatment from about 15% to under 3%.18PubMed Central. Impact of the Composite Allocation Score on Lung Transplant Waitlist and Posttransplant Outcomes These are early results, and long-term data will take years to mature, but the trend is reassuring.
Why the Hospital You Choose Matters
Not all transplant centers produce the same outcomes, and the volume of transplants a center performs each year is a reliable predictor of success. An analysis of over 10,000 patients across 71 U.S. centers found that higher annual volume was linked to better one-year survival, up to a threshold of about 33 transplants per year. Above that number, additional volume did not confer extra benefit.19PubMed Central. The Impact of Center Volume on Outcomes in Lung Transplantation Only about a third of transplant centers met that threshold, meaning the majority of programs in the country were operating below the volume associated with the best outcomes. If you have the ability to choose your center, this is one of the most actionable pieces of information available.
Older Recipients Face Steeper Odds
The number of lung transplants performed in patients aged 65 and older has grown substantially, but age does affect survival. In a retrospective study of nearly 5,800 recipients aged 65 and above, median survival was about 4.4 years, roughly a year shorter than the overall population median. Survival worsened with each additional age bracket, and factors like kidney function, hospitalization at the time of transplant, and receiving a single rather than double lung were independently associated with higher mortality in this group.20PubMed Central. Risk factors for mortality in lung transplant recipients aged ≥65 years: A retrospective cohort study of 5,815 patients in the scientific registry of transplant recipients That does not mean transplantation is inappropriate for older patients. It means the team needs to be especially careful about candidate selection and the choice of procedure.
What Happens When a Transplanted Lung Fails
When a transplanted lung eventually fails, retransplantation is sometimes an option, though it is more contentious. The procedure is rarer, technically more demanding, and carries lower survival rates than a first transplant. One analysis from an international registry found that one-year survival after retransplantation was about 76%, compared with roughly 82% after a primary transplant. The biggest predictor of success was timing: patients retransplanted within the first year of their original surgery had one-year survival of just 50%, while those who waited longer did considerably better at about 81%.21The Annals of Thoracic Surgery. Outcomes and Long-term Survival After Pulmonary Retransplantation: A Single-Center Experience
International registry data confirm that the interval between transplants is one of the strongest prognostic factors, along with donor age and whether the patient needed mechanical ventilation beforehand. Recipients who received double lung transplants both times fared better than those who received single lung transplants both times, with one-year survival of 76% versus 69%.22PubMed Central. Epidemiology, risk factors, and outcomes of lung retransplantation: An analysis of the International Society for Heart and Lung Transplantation Thoracic Transplant Registry The most common reason for retransplantation was chronic graft dysfunction (obliterative bronchiolitis), accounting for about 43% of cases, while primary graft failure accounted for about 17%.
Medication Adherence Has a Surprisingly Large Effect
Every lung transplant recipient must take immunosuppressive drugs for life. These medications prevent the immune system from attacking the donor lung, but they also increase the risk of infection, which creates a delicate balancing act that transplant teams manage continuously.23PubMed Central. Infection, Rejection, and the Connection What many patients do not appreciate is how dramatically skipping or mismanaging those medications affects survival.
One study found that patients who were non-adherent early after transplant had a median survival of just 2.25 years, compared with 5.67 years for those who took their medications as prescribed. Even late non-adherence, developing sloppy habits months or years down the road, was associated with shorter survival: about 5.6 years versus 7.4 years for adherent patients.24PubMed Central. Medication Nonadherence After Lung Transplantation in Adult Recipients A separate study found that patients with good adherence in the first three years had better five-year graft survival (74% versus 60%) and patient survival (79% versus 64%) and lower rates of chronic graft dysfunction.25PLOS ONE. Adherence is associated with a favorable outcome after lung transplantation
The reasons people struggle with adherence are varied and often unexpected. One study found that patients who had returned to work full or part-time were significantly more likely to be non-adherent than those who were not working, probably because feeling healthy and being busy with normal life makes it easier to forget that you depend on continuous medication.26The Open Nursing Journal. Non-adherence to Immunosuppressant after Lung Transplantation – A Common Risk Behavior Depression also raises non-adherence risk. These findings underscore that post-transplant success is not purely a medical problem; it is a behavioral and psychosocial one as well.
Lung Transplants in Children
Pediatric lung transplantation is far less common than adult transplantation, but the outcomes have improved substantially. Worldwide median survival in children is currently about 5.7 years, similar to the adult figure, though experienced centers report median survival exceeding 10 years for selected patients.27PubMed Central. Lung transplantation in children A single-center study of patients transplanted before age 18 reported one-year and five-year patient survival rates of 71% and 57%, respectively, with median patient survival of about 93 months (nearly eight years).28European Respiratory Journal. Lung transplantation in children and young adults: a 20-year single-centre experience Children who eventually need retransplantation can also do well; one analysis noted that outcomes for pediatric transplantation have improved over the past 25 years and are now comparable to adult results, with elective retransplantation contributing to better long-term survival.29PubMed. The influence of retransplantation on survival for pediatric lung transplant recipients
Quality of Life After Transplant
Survival numbers alone do not capture what life is actually like after a lung transplant. Most recipients experience a dramatic improvement in breathing, exercise tolerance, and overall functioning. A randomized study of long-term survivors found that structured rehabilitation improved both sub-maximal and maximal exercise capacity, and that gains in physical fitness were strongly correlated with better quality of life scores.30PubMed. Effect of inpatient rehabilitation on quality of life and exercise capacity in long-term lung transplant survivors: a prospective, randomized study Many recipients who were housebound or on supplemental oxygen before surgery are able to return to work, travel, and exercise moderately. That said, the medication burden, frequent monitoring, and ever-present threat of rejection and infection mean that life after transplant is not carefree. It is a managed condition rather than a cure, but for people facing the alternative of progressive respiratory failure, the trade-off is transformative.
How Outcomes Have Changed Over the Decades
The first human lung transplant was performed in 1963, and the patient survived only 18 days. The combined survival of the first two recipients was just 26 days.31PubMed Central. Historical perspectives of lung transplantation: connecting the dots The first recipient to survive longer than a few months did not come until 1971, and the modern era of reliable lung transplantation did not truly begin until the late 1980s with improved surgical techniques and immunosuppression. Since then, the field has been reshaped by a series of advances: better definitions of graft dysfunction, allocation scoring systems, use of ECMO as a bridge to transplant for patients too sick to wait, acceptance of donors after cardiac death, and the introduction of ex vivo lung perfusion. Each of these innovations has contributed incrementally to the improving survival curve. The median survival of 5.8 years may sound modest compared with other transplanted organs, but placed against the history of a procedure that was once almost uniformly fatal, it reflects remarkable progress in a field still wrestling with the unique biology of the transplanted lung.